Peer-reviewed veterinary case report
Aglepristone helps treat insulin resistance in female dogs
By Bigliardi, Enrico et al.·Published in Journal of veterinary science·2014·Department of Veterinary Science, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Use of aglepristone for the treatment of P4 induced insulin resistance in dogs.
- Species:
- dog
Plain-English summary
A group of female dogs with diabetes was found to have insulin resistance, meaning their blood sugar levels remained high even with insulin treatment. To help, they were given a medication called aglepristone, which works against certain hormones that can interfere with insulin. After starting treatment, their blood sugar levels began to drop significantly by day 12, allowing their insulin doses to be reduced. By the end of the study, their blood sugar was better controlled, showing that aglepristone can be an effective part of managing insulin resistance in diabetic dogs.
People also search for: dog diabetes treatment · insulin resistance in dogs · aglepristone for dogs · managing high blood sugar in dogs
Abstract
Insulin resistance (IR) in dogs is suspected when hyperglycemia is present despite administration of insulin doses greater than 1.0 to 1.5 UI/kg. IR is caused by increases in counter regulatory hormones concentrations (glucagon, glucocorticoids, catecholamines and growth hormone). This study was conducted to investigate the use of aglepristone (RU 46534), a P4 receptor antagonist, for the treatment of IR diabetes mellitus in bitches during the luteal phase. All animals were treated with porcine insulin zinc suspension (Caninsulin) and aglepristone (Alizin) 10 mg/kg subcutaneously at day 1, 2, 9 and 17 from diagnosis. At day 5, no significant variation in glycemia was shown. At day 12 and 20, serum glucose concentrations were significant lower (p < 0.05). From day 12 the insulin dose was reduced to 0.8 IU BID. Insulin was reduced in the following weeks and glycemia was controlled.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24378588/